0000899243-22-031043.txt : 20220914 0000899243-22-031043.hdr.sgml : 20220914 20220914163533 ACCESSION NUMBER: 0000899243-22-031043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220912 FILED AS OF DATE: 20220914 DATE AS OF CHANGE: 20220914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Craig Adam R CENTRAL INDEX KEY: 0001339498 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 221243414 MAIL ADDRESS: STREET 1: C/O INNOVIVE PHARMACEUTICALS, INC. STREET 2: 555 MADISON AVENUE, 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-12 0 0000891293 CTI BIOPHARMA CORP CTIC 0001339498 Craig Adam R 3101 WESTERN AVENUE, SUITE 800 SEATTLE WA 98121 1 1 0 0 President and CEO Common Stock 2022-09-12 4 M 0 242300 0.8411 A 270161 D Common Stock 2022-09-12 4 S 0 242300 6.43 D 27861 D Non-Qualified Stock Option (right to buy) 0.8411 2022-09-12 4 M 0 242300 0.00 D 2029-05-16 Common Stock 242300 913254 D This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. The reporting person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 5,000 shares of common stock purchased by the reporting person on August 16, 2022. The reporting person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.27 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022. /s/ Bruce J. Seeley, attorney-in-fact for Adam R. Craig 2022-09-14